Adult T-cell lymphoma (ATL) is an aggressive and unusual lymphoma of mature T cells. This type of lymphoma is associated with the presence of HTLV-1 virus, which integrates into T-cell genome and determines the lymphoma oncogenesis. 1 The adult T-cell leukemia-lymphoma entity is composed of ATL, acute, chronic, and smoldering subtypes. 2 Patients with ATL have an adverse prognosis with a median survival that ranges between 6 and 12 months because of the low chemosensitivity and the short duration of response with intensified chemotherapy regimens. 2-5 Allogeneic stem cell transplantation (Allo-SCT) has doubled the survival of these patients, so it is currently considered the standard treatment. 1,6,7 Latin America is an endemic HTLV-1 area. Taking into account a virus infection of between 800 000 and 2 500 000 patients, the incidence density in Brazil is estimated at between 427 and 1333 cases of ATL per year. 8-10 A similar incidence was published by Iwanaga et al in Japan. 11 We present this case due to its rarity and good evolution after a mismatch unrelated Allo-SCT, with a reduced intensity conditioning regimen and post-transplant cyclophosphamide. Given that HTLV-1 infection is common in our region and there are few publications about the outcome of these patients, the importance of having local data is highlighted. 5,12 2 | C A S E REP ORT In August of 2018, a 36-year-old man developed dyspnea and dysphagia secondary to a left cervical mass. Targeted studies were performed with diagnosis of a CD4+, CD8+, EBER-, T-cell lymphoma, with a 95% of Ki 67, stage IIE due to tongue involvement in initial PET/CT (see Figure 1). Relevant from the patient's history is that he had a total gastrectomy performed in 2001, due to upper gastrointestinal bleeding. In addition, he had pulmonary tuberculosis in the same year and completed a 18 months treatment with anti-tuberculosis drugs. He also suffered a disseminated strongyloidiasis in 2002, with a new episode in 2006, receiving treatment with ivermectin, albendazole, and thiabendazole. The patient started chemotherapy. He received 6 cycles of CHOEP plus intrathecal therapy from September to December